Wealth Enhancement Trust Services’s Heron Therapeutics HRTX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$137	Buy	+320	New	+$257	﹤0.01%	1393

Other funds holding HRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Wealth Enhancement Trust Services's HRTX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Heron Therapeutics (HRTX) in Q2 2026: 320 shares worth $137. The stake represents ﹤0.01% of the portfolio and ranks #1393 among its holdings.

96 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

Wealth Enhancement Trust Services held 320 shares of Heron Therapeutics worth $137 as of Q2 2026.
Heron Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Heron Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1393 holding.
96 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.